Revenue grew 10.47% YoY to ¥1.378 billion, with net profit down 5.40% due to forex losses, but adjusted profit up nearly 18%. Life sciences led segment growth, gross margin improved, and cash flow from operations surged 53.58%.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.